Who is sponsoring NCT06969534?

NCT06969534 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT06969534?

Interventions in NCT06969534: Pucotenlimab combined with GP regimen.

What condition does NCT06969534 study?

NCT06969534 studies Lymphoepithelioma-like Carcinoma, Lymphoepithelioma, Carcinoma.

Is NCT06969534 still recruiting?

NCT06969534 is currently recruiting now. Last updated 15 May 2025.

Last reviewed 2025-05-15 · How we verify

NCT06969534

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Pucotenlimab in pLECC

Recruiting now Phase 2 Last updated 15 May 2025

What this trial tests

Phase 2 trial testing Pucotenlimab combined with GP regimen in Lymphoepithelioma-like Carcinoma in 33 participants. Currently enrolling.

Timeline

15 May 2025

Primary endpoint
30 December 2027

30 December 2028

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	15 May 2025
Primary completion	30 December 2027
Estimated completion	30 December 2028
Sites	1 location across China

Drugs / interventions tested

Pucotenlimab combined with GP regimen — full drug profile →

Conditions studied

Lymphoepithelioma-like Carcinoma — all drugs for Lymphoepithelioma-like Carcinoma →
Lymphoepithelioma — all drugs for Lymphoepithelioma →
Carcinoma — all drugs for Carcinoma →

Sponsor

Sun Yat-sen University

Who can join

Adults 1 to 18, any sex, with Lymphoepithelioma-like Carcinoma or Lymphoepithelioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lymphoepithelioma-like carcinoma (LELC) in children is a rare epithelial malignant tumor. Regarding pediatric lymphoepithelioma-like carcinoma (pLELC), its clinicopathological features, prognosis, and molecular characteristics remain unknown. In preclinical studies, this study aims to explore the safety and efficacy of the PD-1 monoclonal antibody pucotenlimab combined with the chemotherapy regimen of gemcitabine and cisplatin as the first-line treatment for lymphoepithelioma-like carcinoma in children and adolescents.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06969534 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 15 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06969534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing